A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
1) To evaluate the effectiveness of AST-120 (spherical carbon adsorbent) added to
standard-of-care therapy in moderate to severe Chronic Kidney Disease (CKD), on time to first
occurrence of any event of the triple composite outcome of initiation of dialysis, kidney
transplant or doubling of serum creatinine (sCr) when compared with placebo; 2) To evaluate
the safety and tolerability of long-term AST-120 therapy in patients with CKD; 3) To evaluate
the effects of AST-120 versus placebo, on other measures of renal function.